Sam Brusco, Associate Editor06.29.23
Translumina, an interventional cardiovascular device company with manufacturing presence in Germany and India, has acquired Netherlands-based Blue Medical Devices, a Wellinq group company.
Blue Medical Devices was incorporated in 2013 and makes balloon catheters, including drug-coated balloons (DCB) and other specialty balloons for complex coronary interventions.
Wellinq's CEO, Sander Hartman, told the press, "Becoming part of Translumina, which is an emerging front runner in building a great product- and technology portfolio in coronary and structural heart interventions across the world, marks the beginning of an exciting new chapter for Blue Medical. We are convinced that Blue Medical's next-generation Drug Coated Balloon catheters have a tremendous market opportunity with the global sales and marketing network of Wellinq's long term partner Translumina."
Blue Medical’s EU-MDR approved Protégé NC and Protégé SC catheters, according to the company, overcome the limitations of current DCB technologies, with high efficacy and safety. The tech’s patented drug application prevents drug loss during the device’s advancement to the lesion, resulting in high drug concentration at the targeted site.
The deal will enable Translumina to use the drug application technology in peripheral and neurovascular interventions.
"I am excited to lead Translumina in this new wave of creating global leadership with path breaking technologies. Our German lineage now makes further inroads in Europe with this move to Netherlands, enabling us to offer a broad range of therapy solutions and disruptive innovations that address the unmet patient needs," said Indranil Mukherjee, Group CEO, Global Business.
Blue Medical Devices was incorporated in 2013 and makes balloon catheters, including drug-coated balloons (DCB) and other specialty balloons for complex coronary interventions.
Wellinq's CEO, Sander Hartman, told the press, "Becoming part of Translumina, which is an emerging front runner in building a great product- and technology portfolio in coronary and structural heart interventions across the world, marks the beginning of an exciting new chapter for Blue Medical. We are convinced that Blue Medical's next-generation Drug Coated Balloon catheters have a tremendous market opportunity with the global sales and marketing network of Wellinq's long term partner Translumina."
Blue Medical’s EU-MDR approved Protégé NC and Protégé SC catheters, according to the company, overcome the limitations of current DCB technologies, with high efficacy and safety. The tech’s patented drug application prevents drug loss during the device’s advancement to the lesion, resulting in high drug concentration at the targeted site.
The deal will enable Translumina to use the drug application technology in peripheral and neurovascular interventions.
"I am excited to lead Translumina in this new wave of creating global leadership with path breaking technologies. Our German lineage now makes further inroads in Europe with this move to Netherlands, enabling us to offer a broad range of therapy solutions and disruptive innovations that address the unmet patient needs," said Indranil Mukherjee, Group CEO, Global Business.